Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, discusses the importance of state legislation to boost biosimilar access and uptake.
Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, discusses the importance of state legislation to boost biosimilar access and uptake.
Transcript:
You had the opportunity to provide comment to Minnesota congressional leaders about HF 1516, a bill aimed at increasing patient access to biosimilar. Could you explain what this bill is and why more bills like this are needed?
Tichy:
So, one of the reasons for this bill is that we found there were some barriers to biosimilar implementation. We've seen this in our experience, and it's been noted by other organizations and other health care leaders. One of the biggest barriers is actually sometimes you run into health plans that will prefer an innovator product. And it may be because they have some kind of rebate or some other situation that makes them prefer the innovator product.
We've actually run into scenarios where that innovator product is 3 times more expensive than the biosimilar product. We felt that we needed some incentives to push the practice to be able to use biosimilars, like our providers wanted to use biosimilars, our patients wanted to use a biosimilar, and we were having payers that weren't allowing us to do that.
There's also some of those logistical issues with stocking products. This bill would help get biosimilars treated more similarly to how we treat generic drugs, where we have the dispensing organization decide which product gets used. The payers don't micromanage which generic drug that we use, and the payers do a lot of important things to save cost. And we would just say, trust us to sort of drive to the lowest cost, we'll pass that on. And you can focus on other things where you can bring value to health care and reduce overall health care costs.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.